Global diabetes drug market is expected to surpass US$ 76 Billion by the end of the year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for the growth of the diabetes drug market. Type 2 diabetes is on the rise globally due to growth in obesity trends, sedentary lifestyle and lack of physical activity. Type1 diabetes patient requires less amount diabetes drug, whereas Type 2 diabetes patient is a massive consumer of diabetes drug. Several companies are creating their diabetes drug pipeline and trying to broaden their diabetes drug portfolio which will further boost the global diabetes drug market in the forecast period.
Diabetes is a condition in which the patient has a high blood sugar level over a long drawn period. There are 3 types of diabetes Type 1 diabetes, Type 2 diabetes, and Gestational diabetes. Type 1 diabetes is a condition in which patient pancreas fails to produce enough insulin. It is also called juvenile diabetes. In Type 2 diabetes body cells fail to respond to insulin properly. The third one is Gestational diabetes in which a pregnant woman with no history of diabetes develops high blood sugar level. Globally 90% of the diabetes patients are Type 2 and rest are Type 1 cases.
This report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha-Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid - Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides a complete analysis of Diabetes Drug Market.
Type 2 Diabetes Patients has bigger Consumer Base
In this report, we have categorized the diabetes drug market into two part; type 1 diabetes drug market and type 2 diabetes drug markets.
(DPP) IV Inhibitor Segment has the largest Market in Global Diabetes Drug Market
According to this research, this report provides an in-depth analysis of diabetes drug market form multiple perspectives. Here the global diabetes drug market has been categorized into 3 segments: Oral
Diabetes Drug Market, Injectable Diabetes Drug Market, and Insulin
- Oral Diabetes Drug Market is further sub-divided into 5 categories by drug class- (DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide, and Other Oral Drug markets.
- Injectable Diabetes Drug Market has been further classified into 2 parts - Glucagon-like peptide (GLP) 1 agonist and Amylin receptor agonist market.
- Insulin Market has been further categorized into 4 parts - Rapid - Acting Insulin market, Long Acting Insulin market, Premixed Insulin market, and Other Insulin markets.
United States dominates the Global diabetes drug Market
The regions covered in the report for of type 1 diabetes drug market are the United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan and Canada.
The regions covered for type 2 diabetes drug market - are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan, China, India and Brazil. In addition, we have also covered diabetes population of each of these covered regions along with Type 1 and Type 2 diabetes populations.
Novo Nordisk is the Largest Player in Global Diabetes Drug Market
In this report, a comprehensive assessment of global diabetes drug revenue by five major key players is covered. The key players covered in the report are Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson and Boehringer Ingelheim. This report covers historical sales analysis and forecast along with major factors like diabetes R&D and pipeline of diabetes drug in a separate chapter.
Disease Type - Global Diabetes Drug Market
1. By Type 1 Diabetes Drug Market
2. By Type 2 Diabetes Drug Market
Product - Global Diabetes Drug Market
Oral
1. (DPP) IV inhibitor
2. SGLT-2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug
Injection
1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist
Insulin
1. Rapid - Acting Insulin
2. Long-Acting Insulin
3. Premixed Insulin
4. Other Insulin
Regions - Population Type 1 & Type 2 Diabetes Drug
1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil
Regions - Type 1 Diabetes Drug Market
1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. Canada
Regions - Type 2 Diabetes Drug Market
1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil
Key Players Analysis
1. Novo Nordisk
2. Merck & Co
3. Eli Lilly
4. AstraZeneca
5. Johnson & Johnson
6. Boehringer Ingelheim
Table of Contents
Companies Mentioned
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- Johnson & Johnson
- Merck & Co
- Novo Nordisk
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
